Liver biopsy-proven non-alcoholic fatty liver disease predicts no impact on antiviral response in patients with chronic hepatitis B

Abstract

Objective: The role of Non-Alcoholic Fatty Liver Disease (NAFLD) on antiviral response in Chronic Hepatitis B (CHB) remains unclear. Previous studies mainly focus on the impact of the Non-Alcoholic Fatty Liver (NAFL) on antiviral efficacy, whereas the role of Non-Alcoholic Steatohepatitis (NASH) has not been highlighted. The authors aimed to investigate the association of NAFLD (NAFL and NASH), viral and histological characteristics with antiviral response. Methods: The authors collected data of treatment-naïve CHB patients who underwent liver biopsy. All these patients received antiviral monotherapy and 48-week follow-up. The antiviral response was evaluated by KaplanMeier analysis. Cox regression analysis identified the variables associated with antiviral response. Results: Overall, 120 treatment-naïve CHB patients were enrolled, with 49.2% (59/120) of them were complicated by NAFLD. Male (Odd Ratio [OR = 4.222], 95% Confidence Interval [95% CI 1.620-11.003]) and overweight (OR = 8.709, 95 % CI 3.355-22.606) were independent predictors for concurrent NAFLD. After 48-week follow-up, the authors found that the overall antiviral response did not differ between CHB patients with and without concomitant NAFL/NASH (p > 0.05). High viral load (Hazard Ratio [HR = 0.522], 95% CI 0.286-0.952), advanced fibrosis (HR = 2.426, 95% CI 1.256-4.686), and moderate-to-severe interface hepatitis (HR = 2.541, 95% CI 1.406-4.592) were significantly correlated with antiviral response after 8-week follow-up. Conclusion: Neither NAFL nor NASH had an impact on antiviral therapy for CHB. It was low hepatitis B load, advanced fibrosis, and moderate-to-severe interface hepatitis that contributed to the virological response.